Edesa Biotech (NASDAQ:EDSA – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $21.00 target price on the stock.
Edesa Biotech Trading Up 0.4 %
Edesa Biotech stock opened at $2.39 on Thursday. The firm has a 50-day moving average price of $2.09 and a 200-day moving average price of $2.79. The firm has a market capitalization of $16.71 million, a PE ratio of -1.28 and a beta of 0.77. Edesa Biotech has a 12-month low of $1.55 and a 12-month high of $5.59.
Edesa Biotech (NASDAQ:EDSA – Get Free Report) last released its earnings results on Friday, February 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.17). During the same period in the previous year, the company posted ($0.54) EPS. As a group, sell-side analysts predict that Edesa Biotech will post -1.75 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Edesa Biotech
About Edesa Biotech
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
See Also
- Five stocks we like better than Edesa Biotech
- How to Short Nasdaq: An Easy-to-Follow Guide
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- The 3 Best Blue-Chip Stocks to Buy Now
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.